AR071577A1 - Pirazolo-pirimidinona para el tratamiento de trastornos del sistema nervioso central - Google Patents
Pirazolo-pirimidinona para el tratamiento de trastornos del sistema nervioso centralInfo
- Publication number
- AR071577A1 AR071577A1 ARP090101179A AR071577A1 AR 071577 A1 AR071577 A1 AR 071577A1 AR P090101179 A ARP090101179 A AR P090101179A AR 071577 A1 AR071577 A1 AR 071577A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heterocycloalkyl
- cycloalkyl
- heteroaryl
- alkynyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pregnancy & Childbirth (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Los compuestos se utilizarán para la fabricacion de medicamentos, en particular medicamentos para el tratamiento de la enfermedad de Alzheimer o los síntomas o consecuencias de la misma tales como el déficit de percepcion, de concentracion, de aprendizaje o de memoria. También el uso se refiere a la utilizacion de estos compuestos para la fabricacion de medicamentos para mejorar la percepcion, la concentracion, el aprendizaje y/o la memoria en pacientes que lo necesiten. Reivindicacion 1: Un compuesto caracterizado porque la formula general (1), en la que Hc es un grupo heterociclilo, definido como un sistema de anillos no aromático monocíclico, bicíclico, o tricíclico, en el cual al menos uno, preferiblemente uno a tres, de los átomos de carbono han sido reemplazados con un heteroátomo seleccionado del grupo de nitrogeno, oxígeno y/o -S(O)r- siendo r 0, 1 o 2; R1 es un grupo seleccionado de alquil C1-8-, alquenil C2-8-, alquinil C2-8-, alquil C1-6-S-, alquil C1-6-S-alquil C1-3-, cicloalquil C3-7-, cicloalquil C3-7-alquil C1-6-, cicloalquil C3-7-alquenil C2-6-, cicloalquil C3-7-alquinil C2-6-, heterocicloalquil C3-7-, heterocicloalquil C3-7-alquil C1-6-, heterocicloalquil C3-7-alquenil C2-6-, heterocicloalquil C3-7-alquinil C2-6-, arilo, aril-alquil C1-6-, aril-alquenil C2-6-, aril-alquinil C2-6-, heteroarilo, heteroaril-alquil C1-6-, heteroaril-alquenil C2-6- y heteroaril-alquinil C2-6-, donde los miembros mencionados antes pueden estar opcionalmente sustituidos independientemente uno de otro con uno o más sustituyentes seleccionados del grupo que consiste en fluor, cloro, bromo, yodo, O=, HO-, NC-, O2N-, F3C-, HF2C-, FH2C-, F3C-CH2-, F3C-O-, HF2C-O-, HO-alquil C1-6-, R10-O-alquil C1-6-, R10-S-alquil C1-6-, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, cicloalquil C3-7-, cicloalquil C3-7-alquil C1-6-, cicloalquil C3-7-O, cicloalquil C3-7-alquil C1-6-O-, arilo, aril-alquil C1-6-, heteroarilo, heteroaril-alquil C1-6-, heteroaril-O-, heteroaril-alquil C1-6-O-, N-enlazada-piridina-2-ona, N-enlazada-piridina-2-ona-alquil C1-6-, N-enlazada-piridina-2-ona-alquil C1-6-O, heterocicloalquil C3-7-, heterocicloalquil C3-7-alquil C1-6-, heterocicloalquil C3-7-O- estando el heterocicloalquil C3-7- unido al O mediante uno de sus átomos C del anillo, heterocicloalquil C3-7-alquil C1-6-O- estando el heterocicloalquil C3-7- unido al alquil C1-6- mediante uno de sus átomos C del anillo, (R10)2N-, (R10)2N-alquil C1-6, R10-O-, R10-S-, R10-CO-, R10O-CO-, (R10)2N-CO-, (R10)2N-CO-alquil C1-6, R10-CO-(R10)N-, R10-CO-(R10)N-alquil C1-6-, R10-CO-O-, R10-O-CO-O-, R10O-CO-O-alquil C1-6-, R10O-CO-(R10)N-, R10O-CO-(R10)N-alquil C1-6-, (R10)2N-CO-O-alquil C1-6-, (R10)2N-CO-(R10)N-alquil C1-6-, R10-SO2-(R10)N-, R10-SO2-(R10)N-alquil C1-6-, (R10)2N-SO2-(R10)N-alquil C1-6-, (R10)2N-SO2-, (R10)2N-SO2- alquil C1-6-, y alquil C1-6-SO2-; donde cualquiera de los grupos cicloalquil C3-7-, heterocicloalquil C3-7-, aril-, heteroaril-, N-enlazada-piridina-2-ona, (R10)2N-CO-alquil C1-6-, mencionados antes puede estar opcionalmente sustituido independientemente con uno o más del grupo de fluor, cloro, bromo, HO-, NC-, O2N-, F3C-, HF2C-, FH2C-, F3C-CH2-, F3C-O-, HF2C-O-, heterocicloalquil C3-7-, R10-O-alquil C1-6-, R10-S-alquil C1-6-, alquil C1-6-, (R10)2N-, (R10)2N-alquil C1-6-, R10-O-, R10-S-, R10-CO-, R10O-CO-, (R10)2N-CO-, (R10)2N-CO-alquil C1-6, R10-CO-(R10)N-, R10-CO-(R10)N-alquil C1-6-, R10-CO-O-, R10-O-CO-O-, R10O-CO-O-alquil C1-6-, R10O-CO-(R10)N-, R10O-CO-(R10)N-alquil C1-6-, (R10)2N-CO-O-, (R10)2N-CO-(R10)N-; (R10)2N-SO2-(R10)N-, (R10)2N-CO-O-alquil C1-6-, (R10)2N-CO-(R10)N-alquil C1-6-, R10-SO2-(R10)N-, R10-SO2-(R10)N-alquil C1-6-, (R10)2N-SO2-(R10)N-alquil C1-6-, (R10)2N-SO2-, (R10)2N-SO2-alquil C1-6, y/o alquil C1-6-SO2-; R2 independientemente de cualquier otro R2 es un grupo seleccionado de: H-, fluor, NC-, F3C-, HF2C-, FH2C-, F3C-CH2-, carboxi-, alquil C1-6-, alquenil C2-6-, alquinil C2-6-, alquil C1-6-S-, alquil C1-6-S-alquil C1-3-, preferiblemente alquil C1-6-S-alquil C2-3-, cicloalquil C3-7-, cicloalquil C3-7-alquil C1-6-, cicloalquil C3-7-alquenil C2-6-, cicloalquil C3-7-alquinil C2-6-, heterocicloalquil C3-7-, heterocicloalquil C3-7-alquil C1-6-, heterocicloalquil C3-7-alquenil C2-6-, heterocicloalquil C3-7-alquinil C2-6, arilo, aril-alquil C1-6-, aril-alquenil C2-6-, aril-alquinil C2-6, heteroarilo, heteroaril-alquil C1-6-, heteroaril-alquenil C2-6-, heteroaril-alquinil C2-6-, R10-O-alquil C2-3-, (R10)2N-, R10O-CO-, (R10)2N-CO-, R10-CO-(R10)N-, R10-CO-, (R10)2N-CO-(R10)N-, R10-CO-(R10)N-, R10-SO2-(R10)N-, alquil C1-6-SO2-, =O, donde los miembros mencionados antes pueden estar opcionalmente sustituidos independientemente uno de otro con uno o más sustituyentes seleccionados del grupo que consiste en fluor, cloro, bromo, NC-, O2N-, F3C-, HF2C-, FH2C-, F3C-CH2-, HO-alquil C1-6-, alquil C1-6-O-, alquil C1-6-O-alquil C1-6-, alquil C1-6-, (R10)2N-, (R10)2N-alquil C1-3-, y (R10)2N-CO-, y en los casos en que Hc comprende NR2 como un miembro del anillo, R2 será independientemente de cualquier otro R2: H-, F3C-CH2-, HF2C-CH2-, alquil C1-6, alquenil C2-6-, alquinil C2-6-, alquil C1-6-S-alquil C1-3-, cicloalquil C3-7-, cicloalquil C3-7-alquil C1-6-, cicloalquil C3-7-alquenil C2-6-, cicloalquil C3-7-alquinil C2-6-, heterocicloalquil C3-7-, heterocicloalquil C3-7-alquil C1-6-, heterocicloalquil C3-7-alquenil C2-6-, heterocicloalquil C3-7-alquinil C2-6-, arilo, aril-alquil C1-6-, heteroarilo, heteroaril-alquil C1-6, R10-O-alquil C1-3, R10O-CO-, (R10)2N-CO-, R10-CO-, R10-SO2-, o alquil C1-6-SO2-, donde los miembros mencionados antes pueden estar opcionalmente sustituidos independientemente uno de otro con uno o más sustituyentes seleccionados independientemente del grupo que consiste en fluor, HO-, NC-, O2N-, F3C-, HF2C-, FH2C-, F3C-CH2, HO-alquil C1-6-, R10-O-alquil C1-6-, alquil C1-6-, R10-O-, (R10)2N-, (R10)2N-alquil C1-3-, y (R10)2N-CO-; R3 es independientemente, un grupo seleccionado de H-, hidroxi y R10-O-; R4 y R5 son independientemente uno de otro H-, fluor, F3C-, HF2C-, FH2C-, y alquil C1-3; o R4 y R5 junto con el átomo de carbono al que están unidos forman un grupo cicloalquilo de 3 a 6 miembros, donde los miembros mencionados antes incluyendo el anillo carbocíclico formado, pueden estar opcionalmente sustituidos independientemente uno de otro con uno o más sustituyentes seleccionados del grupo que consiste en fluor, HO-, NC-, O2N-, F3C-, HF2C-, FH2C-, F3C-CH2, HO-alquil C1-6, CH3-O-alquil C1-6-, alquil C1-6-, alquil C1-6-O- y (alquil C1-6-)2N-CO-; R10 independientemente de cualquier otro R10, es un grupo seleccionado de H- (pero no en el caso en que es parte de un grupo que se selecciona de R10O-CO-, R10-SO2 o R10-CO-), F3C-CH2-, alquil C1-6-, alquenil C2-6-, cicloalquil C3-7-, cicloalquil C3-7-alquil C1-3-, heterocicloalquil C3-7, heterocicloalquil C3-7-alquil C1-6-, arilo, aril-alquil C1-3-, heteroarilo, y heteroaril-alquil C1-3-, y en el caso en que dos grupos R10 estén ambos unidos al mismo átomo de nitrogeno pueden formar junto con dicho átomo de nitrogeno un anillo de heterocicloalquilo de 3 a 7 miembros, y donde uno de los grupos -CH2- del anillo heterocicloalquilo formado puede estar reemplazado por -O-, -S-, -NH-, -N(cicloalquil C3-6)-, -N(cicloalquil C3-6-alquil C1-4)- o -N(alquil C1-4)- y, en particular, en el caso de (R10)2N-CO- entonces R10 se selecciona preferiblemente del grupo de piperidinilo, piperazinilo, pirrolidinilo, morfolinilo y tiomorfolinilo, y donde los miembros mencionados antes pueden estar opcionalmente sustituidos independientemente uno de otro con uno o más sustituyentes seleccionados del grupo que consiste en fluor, cloro, bromo, HO-, NC-, O2N-, F3C-, HF2C-, FH2C-, F3C-CH2, HO-alquil C1-6-, CH3-O-alquil C1-6-, alquil C1-6- y alquil C1-6-O-; x es 0, 1, 2, 3 o 4, y preferiblemente es 0, 1 o 2, más preferiblemente 0 o 1 y más preferiblemente 0; y es 0 o 1, preferiblemente 0; y sus sales y solvatos farmacéuticamente aceptables; con la condicion de que si Hc es oxetanilo, que está unido mediante el átomo de carbono proximo al oxígeno del oxetanilo, no hay ningun sustituyente unido a dicho átomo de carbono mediante un separador -CH2-.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08153987 | 2008-04-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR071577A1 true AR071577A1 (es) | 2010-06-30 |
Family
ID=39790395
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090101179 AR071577A1 (es) | 2008-04-02 | 2009-04-01 | Pirazolo-pirimidinona para el tratamiento de trastornos del sistema nervioso central |
Country Status (34)
Country | Link |
---|---|
US (2) | US8623879B2 (es) |
EP (1) | EP2300478B1 (es) |
JP (1) | JP5391264B2 (es) |
KR (1) | KR101623762B1 (es) |
CN (1) | CN101983199B (es) |
AR (1) | AR071577A1 (es) |
AU (1) | AU2009232017B2 (es) |
BR (1) | BRPI0910690B8 (es) |
CA (1) | CA2716410C (es) |
CL (1) | CL2009000800A1 (es) |
CO (1) | CO6321264A2 (es) |
CY (1) | CY1117626T1 (es) |
DK (1) | DK2300478T3 (es) |
EA (1) | EA021504B1 (es) |
EC (1) | ECSP10010506A (es) |
ES (1) | ES2573330T3 (es) |
HK (1) | HK1149549A1 (es) |
HR (1) | HRP20160683T2 (es) |
HU (1) | HUE027771T2 (es) |
IL (1) | IL207710A (es) |
MA (1) | MA32201B1 (es) |
ME (1) | ME02427B (es) |
MX (1) | MX2010010821A (es) |
MY (2) | MY182670A (es) |
NZ (1) | NZ588245A (es) |
PE (1) | PE20091756A1 (es) |
PL (1) | PL2300478T3 (es) |
RS (1) | RS54724B1 (es) |
SG (1) | SG189706A1 (es) |
SI (1) | SI2300478T1 (es) |
TW (1) | TWI433850B (es) |
UA (1) | UA105362C2 (es) |
UY (1) | UY31748A (es) |
WO (1) | WO2009121919A1 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
DE102004001873A1 (de) | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
EP2217602B1 (en) | 2007-11-30 | 2018-08-29 | Boehringer Ingelheim International GmbH | 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
CA2736304A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
MX2011010184A (es) * | 2009-03-31 | 2011-10-28 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4 -ona y su uso como moduladores de pde9a. |
MY170189A (en) * | 2010-08-12 | 2019-07-09 | Boehringer Ingelheim Int | 6-cycloalkyl-1, 5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
JP5888237B2 (ja) | 2010-09-07 | 2016-03-16 | アステラス製薬株式会社 | ピラゾロキノリン化合物 |
US20130040971A1 (en) * | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
US8809345B2 (en) | 2011-02-15 | 2014-08-19 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders |
MX341269B (es) | 2011-03-02 | 2016-08-09 | Bayer Ip Gmbh | Proceso para preparar derivados de acido arilacetico y heteroarilacetico. |
CN102260266B (zh) * | 2011-05-03 | 2013-08-28 | 中山大学 | 吡唑并[3,4-d]嘧啶酮类化合物及其在制备磷酸二酯酶Ⅸ抑制剂中的应用 |
US9012489B2 (en) | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
RU2605096C2 (ru) * | 2011-10-07 | 2016-12-20 | ЭЙСАЙ АрЭНДДи МЕНЕДЖМЕНТ КО., ЛТД. | Пиразолохинолиновое производное |
EP2647377A1 (en) | 2012-04-06 | 2013-10-09 | Sanofi | Use of an h3 receptor antagonist for the treatment of alzheimer's disease |
PL400149A1 (pl) * | 2012-07-26 | 2014-02-03 | Celon Pharma Spólka Z Ograniczona Odpowiedzialnoscia | Pochodne pirazolo[3,4-d]pirymidyno-4(5H)-onu jako inhibitory PDE9 |
CN102786525B (zh) * | 2012-08-08 | 2014-12-17 | 中山大学 | N-取代吡唑并[3,4-d]嘧啶酮类化合物、其制备方法及其应用 |
US9156847B2 (en) * | 2013-03-15 | 2015-10-13 | Janssen Pharmaceutica Nv | Processes and intermediates for preparing a medicament |
JP6777398B2 (ja) * | 2013-03-15 | 2020-10-28 | ヤンセン ファーマシューティカ エヌ.ベー. | 薬剤を調製するための方法と中間体 |
RU2655171C2 (ru) | 2013-04-05 | 2018-05-24 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Соль производного пиразолохинолина и ее кристалл |
WO2014163146A1 (ja) | 2013-04-05 | 2014-10-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピリジニルピラゾロキノリン化合物 |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
AR103297A1 (es) * | 2014-12-30 | 2017-05-03 | Forma Therapeutics Inc | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina |
WO2016126929A1 (en) | 2015-02-05 | 2016-08-11 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
JP2018504430A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス,インコーポレイテッド | ユビキチン特異的プロテアーゼ7阻害物質としてのキナゾリノン及びアザキナゾリノン |
JP2018504432A (ja) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス,インコーポレイテッド | ユビキチン特異的プロテアーゼ7阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
ES2967489T3 (es) * | 2016-10-18 | 2024-04-30 | H Lundbeck As | Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1 |
MX2019004859A (es) | 2016-10-28 | 2019-06-20 | H Lundbeck As | Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas. |
CA3041607A1 (en) | 2016-10-28 | 2018-05-03 | H. Lundbeck A/S | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
KR102643197B1 (ko) * | 2017-02-23 | 2024-03-06 | 베링거 인겔하임 인터내셔날 게엠베하 | 화합물 iii의 새로운 의학 용도 |
IL270395B (en) | 2017-06-01 | 2022-08-01 | Eisai R&D Man Co Ltd | A therapeutic agent for dementia that combines a pyrozoloquinoline derivative and donepezil |
WO2018221550A1 (ja) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
BR112019023552A2 (pt) | 2017-06-01 | 2020-06-02 | Eisai R&D Management Co., Ltd. | Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina |
US11484502B2 (en) | 2017-06-01 | 2022-11-01 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition comprising PDE9 inhibitor |
TW201902898A (zh) | 2017-06-08 | 2019-01-16 | 美商默沙東藥廠 | 吡唑并嘧啶pde9抑制劑 |
CN111630055B (zh) * | 2018-02-02 | 2023-07-14 | 勃林格殷格翰国际有限公司 | 用作饥饿素o-酰基转移酶(goat)抑制剂的吡唑取代的和吲唑取代的噁二唑并吡啶衍生物 |
CN110357888A (zh) * | 2018-04-09 | 2019-10-22 | 南京药捷安康生物科技有限公司 | 杂环磷酸二酯酶抑制剂及其用途 |
WO2020076752A1 (en) * | 2018-10-08 | 2020-04-16 | The Johns Hopkins University | Use of pde9 inhibitors for treatment |
CN111471059B (zh) | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
CN110339197A (zh) * | 2019-06-24 | 2019-10-18 | 中山大学 | 一种防治血管性痴呆的磷酸二酯酶9a抑制剂的用途 |
CN113200986A (zh) * | 2021-04-29 | 2021-08-03 | 湖南华腾制药有限公司 | 一种伊布替尼中间体的制备方法 |
Family Cites Families (183)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3165520A (en) * | 1965-01-12 | Certificate of correction | ||
US258651A (en) | 1882-05-30 | Dissected toy picture | ||
US3169965A (en) * | 1965-02-16 | New x-mercapto-pyrazolo | ||
US2524898A (en) | 1947-03-25 | 1950-10-10 | Dumas Jean | Painter's easel |
GB937723A (en) | 1960-05-11 | 1963-09-25 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
DE1149013B (de) | 1960-05-11 | 1963-05-22 | Ciba Geigy | Verfahren zur Herstellung von 4-Oxo-4, 5-dihydro-pyrazolo-[3, 4-d]Pyrimidinen |
CH396927A (de) | 1960-05-11 | 1965-08-15 | Ciba Geigy | Verfahren zur Herstellung neuer Pyrazolopyrimidine |
DE1156415B (de) | 1960-05-11 | 1963-10-31 | Ciba Geigy | Verfahren zur Herstellung von 1-Isopropyl-4-hydroxy-pyrazolo [3, 4-d]-pyrimidinen |
CH396925A (de) | 1960-05-11 | 1965-08-15 | Ciba Geigy | Verfahren zur Herstellung neuer Pyrazolopyrimidine |
CH396923A (de) | 1960-05-11 | 1965-08-15 | Ciba Geigy | Verfahren zur Herstellung von 4-Mercapto-pyrazolo(3,4-d)pyrimidinen |
ES267249A1 (es) | 1960-05-11 | 1961-11-01 | Ciba Geigy | Procedimiento para la obtencion de pirazolo-pirimidinas nuevas |
CH396924A (de) | 1960-05-11 | 1965-08-15 | Ciba Geigy | Verfahren zur Herstellung von 4-Mercapto-pyrazolo(3,4-d)pyrimidinen |
CH398626A (de) * | 1960-05-11 | 1966-03-15 | Ciba Geigy | Verfahren zur Herstellung neuer Pyrazolopyrimidine |
GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
CH396926A (de) | 1960-05-11 | 1965-08-15 | Ciba Geigy | Verfahren zur Herstellung neuer Pyrazolopyrimidine |
DE1147234B (de) | 1960-05-11 | 1963-04-18 | Ciba Geigy | Verfahren zur Herstellung von 1-Isopropyl-4-hydroxy-6-benzyl-pyrazolo[3, 4-d]pyrimidin |
DE1161281B (de) | 1960-05-11 | 1964-01-16 | Ciba Aktiengesellschaft, Basel (Schweiz) | Verfahren zur Herstellung von 1-Alkyl-6-aralkyl-pyrazoloÄ3,4-dÜ-pyrimidinen. |
DE1153023B (de) | 1960-05-11 | 1963-08-22 | Ciba Geigy | Verfahren zur Herstellung von 4-Hydroxy-pyrazolo[3,4-d] pyrimidinen |
US3244328A (en) * | 1964-03-23 | 1966-04-05 | Corning Glass Works | Dispensing from plural sources |
US3732225A (en) * | 1970-07-23 | 1973-05-08 | Squibb & Sons Inc | Pyrazolo(3,4-d)pyrimidine derivatives |
NL167151C (nl) * | 1971-04-09 | 1981-11-16 | Acf Chemiefarma Nv | Werkwijze ter bereiding van geneesmiddelen met anti-parasitaire werking op basis van halogeen bevatten- de 2,2'-methyleendifenolderivaten, alsmede werkwijze ter bereiding van deze geneeskrachtige verbindingen. |
US3847908A (en) | 1973-03-05 | 1974-11-12 | Squibb & Sons Inc | 6-styrylpyrazolo(3,4-d)pyrimidinones and pyrimidines |
GR82004B (es) | 1983-06-30 | 1984-12-12 | American Home Prod | |
US4602023A (en) * | 1985-06-03 | 1986-07-22 | Warner-Lambert Company | Diphenic acid monoamides |
DE3739366A1 (de) | 1987-04-10 | 1988-10-27 | Boehringer Mannheim Gmbh | Desaza-purin-nucleosid-derivate, verfahren zu deren herstellung sowie deren verwendung bei der nucleinsaeure-sequenzierung sowie als antivirale mittel |
US6211158B1 (en) * | 1987-04-10 | 2001-04-03 | Roche Diagnostics Gmbh | Desazapurine-nucleotide derivatives, processes for the preparation thereof, pharmaceutical compositions containing them and the use thereof for nucleic acid sequencing and as antiviral agents |
US5270315A (en) * | 1988-04-11 | 1993-12-14 | Biochem Pharma Inc. | 4-(purinyl bases)-substituted-1,3-dioxlanes |
US5684164A (en) * | 1988-04-11 | 1997-11-04 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
US5041449A (en) * | 1988-04-11 | 1991-08-20 | Iaf Biochem International, Inc. | 4-(nucleoside base)-substituted-1,3-dioxolanes useful for treatment of retroviral infections |
US5047407A (en) * | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
US5466806A (en) * | 1989-02-08 | 1995-11-14 | Biochem Pharma Inc. | Processes for preparing substituted 1,3-oxathiolanes with antiviral properties |
US7119202B1 (en) * | 1989-02-08 | 2006-10-10 | Glaxo Wellcome Inc. | Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties |
US6350753B1 (en) * | 1988-04-11 | 2002-02-26 | Biochem Pharma Inc. | 2-Substituted-4-substituted-1,3-dioxolanes and use thereof |
US6903224B2 (en) * | 1988-04-11 | 2005-06-07 | Biochem Pharma Inc. | Substituted 1,3-oxathiolanes |
EP0674634B1 (en) | 1989-02-08 | 2003-04-16 | Biochem Pharma Inc | Process for preparing substituted 1,3-oxathiolanes with antiviral properties |
JP2619710B2 (ja) * | 1989-02-27 | 1997-06-11 | 日本製紙 株式会社 | 2′,3′−ジデオキシプリンヌクレオシド類の製造方法 |
US5113855A (en) * | 1990-02-14 | 1992-05-19 | Newhouse Michael T | Powder inhaler |
US5201308A (en) * | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
US5002949A (en) * | 1990-05-01 | 1991-03-26 | American Home Products Corporation | 5-substituted-6-aminopyrimidine derivatives |
DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
GB9027234D0 (en) * | 1990-12-15 | 1991-02-06 | Harris Pharma Ltd | An inhalation device |
CA2100863A1 (en) | 1991-01-23 | 1992-07-24 | David A. Bullough | Adenosine kinase inhibitors |
FR2676929B1 (fr) * | 1991-05-30 | 1994-02-11 | Aerosols Bouchage Ste Fse | Inhalateur de poudres. |
US5341801A (en) * | 1991-12-03 | 1994-08-30 | Sandoz Ltd. | Inhaler |
US5294612A (en) * | 1992-03-30 | 1994-03-15 | Sterling Winthrop Inc. | 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof |
FR2700279B1 (fr) * | 1993-01-14 | 1995-03-17 | Valois | Dispositif portatif pour projeter des doses d'une substance fluide à l'aide d'un flux d'air comprimé. |
IL108523A0 (en) | 1993-02-03 | 1994-05-30 | Gensia Inc | Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain |
US5256668A (en) * | 1993-03-17 | 1993-10-26 | American Home Products Corporation | Aminopyrimidine derivatives as antiviral agents for respiratory syncytial virus |
AU684779B2 (en) * | 1993-05-12 | 1998-01-08 | Teijin Limited | Device and method for dispensing powdered medicine in multiple doses |
DK0626387T3 (da) * | 1993-05-12 | 1999-09-27 | Novartis Ag | Nukleosider og oligonukleotider med 2'-ethergrupper |
WO1995010506A1 (en) | 1993-10-12 | 1995-04-20 | The Du Pont Merck Pharmaceutical Company | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
DK0679657T3 (da) | 1994-04-27 | 2003-10-27 | Novartis Ag | Nukleosider og oligonukleotider med 2'-ethergrupper |
GB9423910D0 (en) * | 1994-11-26 | 1995-01-11 | Pfizer Ltd | Therapeutic agents |
US5656629A (en) * | 1995-03-10 | 1997-08-12 | Sanofi Winthrop, Inc. | 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof |
US6072051A (en) | 1995-11-02 | 2000-06-06 | Chong Kun Dang Corp. | Nucleoside derivatives and process for preparing the same |
JP2000512630A (ja) | 1996-06-06 | 2000-09-26 | ノバルティス アクチエンゲゼルシャフト | 2’―置換ヌクレオシドおよびオリゴヌクレオチド誘導体 |
WO1998000434A1 (en) | 1996-06-28 | 1998-01-08 | Novartis Ag | Modified oligonucleotides |
US6110471A (en) | 1996-09-13 | 2000-08-29 | The Board Of Trustees Of The Leland Stanford Junior University | Non-hormonal method of contraception |
US6509320B1 (en) * | 1996-10-16 | 2003-01-21 | Icn Pharmaceuticals, Inc. | Purine L-nucleosides, analogs and uses thereof |
KR100412480B1 (ko) | 1996-10-16 | 2003-12-31 | 아이씨엔 파마슈티컬스, 인코포레이티드 | 푸린 l-누클레오시드, 이의 유사체 및 이들의 용도 |
US5985627A (en) | 1997-02-28 | 1999-11-16 | Carlsberg Laboratory | Modified carboxypeptidase |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
US5948812A (en) * | 1997-06-09 | 1999-09-07 | Givaudan Roure (International) Sa | 1,7-dioxacycloalkan-8-one compounds |
US5969499A (en) * | 1997-09-10 | 1999-10-19 | Shaffer; Randall A | Controller for AC motor |
KR20010041015A (ko) | 1998-02-17 | 2001-05-15 | 윌리엄 제이. 리플린 | 항바이러스성 피리미딘 유도체 |
DE19838705A1 (de) | 1998-08-26 | 2000-03-02 | Bayer Ag | Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one |
AR023052A1 (es) | 1998-09-25 | 2002-09-04 | Mitsuharu Yoshimura Milton | Derivados de pirimidona |
GB9823103D0 (en) | 1998-10-23 | 1998-12-16 | Pfizer Ltd | Pharmaceutically active compounds |
CA2348979A1 (en) * | 1998-11-02 | 2000-05-11 | Merck & Co., Inc. | Method of treating migraines and pharmaceutical compositions |
US6225315B1 (en) * | 1998-11-30 | 2001-05-01 | Pfizer Inc | Method of treating nitrate-induced tolerance |
US6100037A (en) | 1999-01-07 | 2000-08-08 | Incyte Pharmaceuticals, Inc. | Human cyclic nucleotide PDEs |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
US6515117B2 (en) * | 1999-10-12 | 2003-02-04 | Bristol-Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
EP1104676A1 (en) | 1999-11-30 | 2001-06-06 | Boehringer Ingelheim Vetmedica Gmbh | Safe attenuated bovine viral diarrhea viruses for use in pregnant cows |
PL364995A1 (en) | 2000-02-18 | 2004-12-27 | Shire Biochem Inc. | Method for the treatment or prevention of flavivirus |
US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
US6369222B1 (en) | 2000-07-18 | 2002-04-09 | Hoffmann-La Roche Inc. | mGluR antagonists and a method for their synthesis |
EP1307201B1 (de) | 2000-08-01 | 2004-11-24 | Bayer HealthCare AG | Selektive pde 2-inhibitoren als arzneimittel zur verbesserung der wahrnehmung |
AU2001277621A1 (en) | 2000-08-09 | 2002-03-04 | Astrazeneca Ab | Antiangiogenic bicyclic derivatives |
AU2001289826A1 (en) * | 2000-08-24 | 2002-03-04 | Novartis Ag | Process for surface modifying substrates and modified substrates resulting therefrom |
US6581338B2 (en) * | 2000-10-20 | 2003-06-24 | Myron N. Koenig | Escapable area well cover |
US20020074774A1 (en) * | 2000-12-14 | 2002-06-20 | Davin Hsu | Adjustable handle of umbrella stroller by telescoping and swiveling |
GB0100621D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VI |
AU2002243791B2 (en) | 2001-01-22 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase |
TWI255817B (en) * | 2001-02-14 | 2006-06-01 | Kissei Pharmaceutical | Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof |
DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
US6936590B2 (en) * | 2001-03-13 | 2005-08-30 | Bristol Myers Squibb Company | C-aryl glucoside SGLT2 inhibitors and method |
GB0106661D0 (en) | 2001-03-16 | 2001-05-09 | Pfizer Ltd | Pharmaceutically active compounds |
DK1385856T3 (da) * | 2001-04-11 | 2006-05-15 | Bristol Myers Squibb Co | Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder |
JPWO2002086160A1 (ja) * | 2001-04-18 | 2004-08-12 | 三菱レイヨン株式会社 | ハイブリダイゼーションプローブ |
WO2002098864A1 (en) | 2001-06-01 | 2002-12-12 | F. Hoffmann-La Roche Ag | Pyrimidine, triazine and pyrazine derivatives as glutamate receptors |
CA2450167A1 (en) * | 2001-06-12 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Macrocycles useful in the treatment of alzheimer's disease |
DE60118801T2 (de) | 2001-07-25 | 2006-11-02 | PPG Industries Ohio, Inc., Cleveland | Polymermischung mit hohem brechungsindex |
EP1283226A1 (en) | 2001-07-31 | 2003-02-12 | Resolution Research Nederland B.V. | Hydroxyl-functional copolymer and coating compositions formed therewith |
US6962991B2 (en) | 2001-09-12 | 2005-11-08 | Epoch Biosciences, Inc. | Process for the synthesis of pyrazolopyrimidines |
WO2003031458A1 (en) | 2001-10-12 | 2003-04-17 | Dana-Farber Cancer Institute | Methods for synthesis of diarylmethanes |
HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
KR20040053210A (ko) | 2001-11-02 | 2004-06-23 | 화이자 프로덕츠 인크. | Pde9 억제제를 사용한 인슐린 저항 증후군 및 2형당뇨병의 치료 |
US20030195205A1 (en) * | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
DE10156249A1 (de) | 2001-11-15 | 2003-05-28 | Bayer Ag | Regulation der cGMP-spezifischen Phosphodiesterase 9A |
RU2004128943A (ru) | 2002-02-28 | 2005-04-20 | Байота, Инк. (Us) | Средства, имитирующие нуклеотиды, и их пролекарственные формы |
DE10219435A1 (de) | 2002-05-02 | 2003-11-13 | Bayer Cropscience Ag | Substituierte Pyrazolo-pyrimidin-4-one |
US20040014957A1 (en) | 2002-05-24 | 2004-01-22 | Anne Eldrup | Oligonucleotides having modified nucleoside units |
BR0312271A (pt) | 2002-06-28 | 2007-11-06 | Idenix Cayman Ltd | compostos, composições e seus usos para o tratamento de infecções por flaviviridae |
DE10238725A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Cropscience Ag | Substituierte Heterocyclypyrimidine |
DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
KR100942073B1 (ko) | 2002-08-23 | 2010-02-12 | 기린 홀딩스 가부시키가이샤 | TGF β 저해 활성을 갖는 화합물 및 그것을 포함하여 이루어지는 의약 조성물 |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
DE10244795A1 (de) * | 2002-09-26 | 2004-04-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverinhalator |
DK1576138T3 (en) | 2002-11-15 | 2017-05-01 | Idenix Pharmaceuticals Llc | 2'-METHYL NUCLEOSIDES IN COMBINATION WITH INTERFERON AND FLAVIVIRIDAE MUTATION |
BR0317929A (pt) * | 2003-01-03 | 2006-04-11 | Bristol Myers Squibb Co | métodos de produzir inibidores de sglt2 de glicosìdeo de c-arila |
ES2289377T3 (es) | 2003-03-18 | 2008-02-01 | The Jordanian Pharmaceutical Manufacturing Co. Ltd. | Nuevas pirazolopirimidonas y su uso como inhibidores de pde. |
US20040220186A1 (en) * | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
DE10320785A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Arylmethyl-substituierte Pyrazolopyrimidine |
WO2004099211A1 (de) * | 2003-05-09 | 2004-11-18 | Bayer Healthcare Ag | 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine |
US8044060B2 (en) * | 2003-05-09 | 2011-10-25 | Boehringer Ingelheim International Gmbh | 6-cyclylmethyl- and 6-alkylmethyl pyrazolo[3,4-D]pyrimidines, methods for their preparation and methods for their use to treat impairments of perception, concentration learning and/or memory |
DE602004025803D1 (de) | 2003-06-06 | 2010-04-15 | Arexis Ab | Verwendung von kondensierten heterozyklischen verbindungen als scce-hemmern zur behandlung von hautzuständen |
DE10328479A1 (de) * | 2003-06-25 | 2005-01-13 | Bayer Ag | 6-Arylamino-5-cyano-4-pyrimidinone |
DE502004008951D1 (de) | 2003-08-26 | 2009-03-19 | Boehringer Ingelheim Pharma | Glucopyranosyloxy-pyrazole, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung |
US7375090B2 (en) * | 2003-08-26 | 2008-05-20 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-pyrazoles, pharmaceutical compositions containing these compounds, the use thereof and processed for the preparation thereof |
US7351827B2 (en) | 2003-11-21 | 2008-04-01 | The University Of Connecticut | Substituted oxetanes, method of making, and method of use thereof |
US7371732B2 (en) * | 2003-12-22 | 2008-05-13 | Boehringer Ingelheim International Gmbh | Glucopyranosyloxy-substituted aromatic compounds, medicaments containing such compounds, their use and process for their manufacture |
DE102004001873A1 (de) | 2004-01-14 | 2005-09-29 | Bayer Healthcare Ag | Cyanopyrimidinone |
DE102004012093A1 (de) * | 2004-03-05 | 2005-09-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pulverinhalator mit Merkanaldüse |
KR20120007088A (ko) * | 2004-03-16 | 2012-01-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 글루코피라노실-치환된 벤졸 유도체, 당해 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법 |
US7393836B2 (en) * | 2004-07-06 | 2008-07-01 | Boehringer Ingelheim International Gmbh | D-xylopyranosyl-substituted phenyl derivatives, medicaments containing such compounds, their use and process for their manufacture |
JP2008508213A (ja) * | 2004-07-27 | 2008-03-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | D−グルコピラノシル−フェニル置換環状体、そのような化合物を含有する医薬品、それらの使用及びその製造方法 |
DE102004048388A1 (de) * | 2004-10-01 | 2006-04-06 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | D-Pyranosyl-substituierte Phenyle, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung |
ATE407938T1 (de) * | 2004-12-16 | 2008-09-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte benzen-derivate, medikamente mit solchen verbindungen, ihre verwendung und herstellungsverfahren dafür |
DOP2006000009A (es) | 2005-01-13 | 2006-08-15 | Arena Pharm Inc | Procedimiento para preparar eteres de pirazolo [3,4-d] pirimidina |
ME02012B (me) | 2005-02-04 | 2013-02-28 | Millennium Pharm Inc | INHIBITORI El AKTIVIRAJUĆIH ENZIMA |
CA2595257A1 (en) | 2005-02-23 | 2006-08-31 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted ((hetero)arylethynyl-benzyl)-benzene derivatives and use thereof as sodium-dependent glucose cotransporter 2 (sglt2) inhibitors |
WO2006091905A1 (en) | 2005-02-25 | 2006-08-31 | Gilead Sciences, Inc. | Bicyclo (3.1.0) hexane derivatives as antiviral compounds |
ATE453656T1 (de) * | 2005-04-15 | 2010-01-15 | Boehringer Ingelheim Int | Glucopyranosyl-substituierte (heteroaryloxy- benzyl)-benzen-derivate als sglt-inhibitoren |
UA91546C2 (uk) | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
US7723309B2 (en) | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
DE102005024493A1 (de) | 2005-05-27 | 2006-11-30 | Bayer Healthcare Ag | Verwendung von Pyrazolopyrimidinen |
DE602006014411D1 (de) | 2005-07-27 | 2010-07-01 | Boehringer Ingelheim Pharma | Glucopyranosyl-substituierte ((hetero)cycloalyklethynyl-benzyl)-benzenderivative und deren verwendung als inhibitoren des natriumabhängigen glucose-cotransporters (sglt) |
WO2007025043A2 (en) | 2005-08-23 | 2007-03-01 | Idenix Pharmaceuticals, Inc. | Seven-membered ring nucleosides |
CA2620566A1 (en) * | 2005-08-30 | 2007-03-08 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
AR056195A1 (es) | 2005-09-15 | 2007-09-26 | Boehringer Ingelheim Int | Procedimientos para preparar derivados de (etinil-bencil)-benceno sustituidos de glucopiranosilo y compuestos intermedios de los mismos |
US7488766B2 (en) * | 2005-10-06 | 2009-02-10 | Sabic Innovative Plastics Ip B.V. | Polymer composition, method, and article |
TW200815361A (en) | 2005-10-20 | 2008-04-01 | Astrazeneca Ab | Chemical compounds |
EP1989191B1 (en) | 2006-02-15 | 2011-07-20 | Boehringer Ingelheim International GmbH | Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture |
DE102006016903A1 (de) * | 2006-04-11 | 2007-10-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Inhalator |
EP1844805A1 (de) * | 2006-04-13 | 2007-10-17 | Boehringer Ingelheim Pharma GmbH & Co.KG | Inhalator |
PE20080697A1 (es) | 2006-05-03 | 2008-08-05 | Boehringer Ingelheim Int | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmaceuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion |
PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
US7842672B2 (en) | 2006-07-07 | 2010-11-30 | Gilead Sciences, Inc. | Phosphonate inhibitors of HCV |
JP5384343B2 (ja) | 2006-08-15 | 2014-01-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | グルコピラノシル−置換シクロプロピルベンゼン誘導体、そのような化合物を含む医薬組成物、sglt阻害剤としてのそれらの使用及びそれらの製造方法 |
DE102006044752A1 (de) | 2006-09-20 | 2008-04-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Kolbendosierer |
CA2664095A1 (en) * | 2006-09-21 | 2008-03-27 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted difluorobenzyl-benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2008049923A1 (en) | 2006-10-27 | 2008-05-02 | Boehringer Ingelheim International Gmbh | CRYSTALLINE FORM OF 4-(ß-D-GLUCOPYRANOS-1-YL)-1-METHYL-2-[4-((S)-TETRAHYDROFURAN-3-YLOXY)-BENZYL]-BENZENE, A METHOD FOR ITS PREPARATION AND THE USE THEREOF FOR PREPARING MEDICAMENTS |
WO2008055870A1 (en) | 2006-11-06 | 2008-05-15 | Boehringer Ingelheim International Gmbh | Glucopyranosyl-substituted benzyl-benzonitrile derivatives, medicaments containing such compounds, their use and process for their manufacture |
CL2007003227A1 (es) | 2006-11-09 | 2008-07-04 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras. |
WO2008055959A1 (en) | 2006-11-09 | 2008-05-15 | Galapagos N.V. | Novel compounds useful for the treatment of degenerative & inflammatory diseases |
JP2008183929A (ja) * | 2007-01-26 | 2008-08-14 | Toshiba Corp | Vorモニタ受信装置及びvorモニタ受信方法 |
TW200838549A (en) | 2007-01-26 | 2008-10-01 | Boehringer Ingelheim Int | Methods for preventing and treating neurodegenerative disorders |
WO2008100447A2 (en) | 2007-02-09 | 2008-08-21 | Gilead Sciences, Inc. | Nucleoside analogs for antiviral treatment |
EP2125768A1 (en) | 2007-02-21 | 2009-12-02 | Boehringer Ingelheim International GmbH | Tetrasubstituted glucopyranosylated benzene derivatives, medicaments containing such compounds, their use and process for their manufacture |
WO2008104077A1 (en) | 2007-02-28 | 2008-09-04 | Methylgene Inc. | Small molecule inhibitors of protein arginine methyltransferases (prmts) |
GEP20125405B (en) * | 2007-05-11 | 2012-02-27 | Pfizer | Amino-heterocyclic compounds |
PE20090603A1 (es) | 2007-08-16 | 2009-06-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv |
GEP20125635B (en) | 2007-11-13 | 2012-09-10 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
EP2217602B1 (en) | 2007-11-30 | 2018-08-29 | Boehringer Ingelheim International GmbH | 1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one derivatives and their use as pde9a modulators for the treatment of cns disorders |
JP2011512209A (ja) | 2008-02-20 | 2011-04-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 粉末吸入器 |
US20090235929A1 (en) * | 2008-03-19 | 2009-09-24 | Marc Egen | Powder inhalers |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
CA2736304A1 (en) | 2008-09-08 | 2010-03-11 | Boehringer Ingelheim International Gmbh | Pyrazolopyrimidines and their use for the treatment of cns disorders |
SI2395983T1 (sl) | 2009-02-13 | 2020-08-31 | Boehringer Ingelheim International Gmbh | Farmacevtski sestavek, ki obsega SGLT2 inhibitor, DPP-IV inhibitor in po izbiri nadaljnje antidiabetično sredstvo in uporabe le-teh |
UY32427A (es) | 2009-02-13 | 2010-09-30 | Boheringer Ingelheim Internat Gmbh | Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma |
MY161472A (en) | 2009-02-13 | 2017-04-14 | Boehringer Ingelheim Int | Sglt-2 inhibitor for treating type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance or hyperglycemia |
US20110014284A1 (en) | 2009-02-13 | 2011-01-20 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
MX2011010184A (es) | 2009-03-31 | 2011-10-28 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4 -ona y su uso como moduladores de pde9a. |
AR077859A1 (es) | 2009-08-12 | 2011-09-28 | Boehringer Ingelheim Int | Compuestos para el tratamiento de trastornos del snc |
HUE029381T2 (en) | 2009-09-30 | 2017-02-28 | Boehringer Ingelheim Int | A method for preparing a crystalline form of 1-chloro-4- (beta-D-glucopyranos-1-yl) -2- [4 - ((S) -tetrahydrofuran-3-yloxy) benzyl] benzene. |
IN2012DN02751A (es) | 2009-09-30 | 2015-09-18 | Boehringer Ingelheim Int | |
UY32919A (es) | 2009-10-02 | 2011-04-29 | Boehringer Ingelheim Int | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos |
MY170189A (en) | 2010-08-12 | 2019-07-09 | Boehringer Ingelheim Int | 6-cycloalkyl-1, 5-dihydro-pyrazolo[3,4-d] pyrimidin-4-one derivatives and their use as pde9a inhibitors |
CN103298474B (zh) | 2010-11-10 | 2016-06-29 | 无限药品股份有限公司 | 杂环化合物及其用途 |
US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
-
2009
- 2009-01-04 UA UAA201012717A patent/UA105362C2/uk unknown
- 2009-04-01 MX MX2010010821A patent/MX2010010821A/es active IP Right Grant
- 2009-04-01 EA EA201001518A patent/EA021504B1/ru not_active IP Right Cessation
- 2009-04-01 AU AU2009232017A patent/AU2009232017B2/en active Active
- 2009-04-01 ME MEP-2016-75A patent/ME02427B/me unknown
- 2009-04-01 MY MYPI2014001750A patent/MY182670A/en unknown
- 2009-04-01 DK DK09727328.8T patent/DK2300478T3/en active
- 2009-04-01 CL CL2009000800A patent/CL2009000800A1/es unknown
- 2009-04-01 ES ES09727328.8T patent/ES2573330T3/es active Active
- 2009-04-01 BR BRPI0910690A patent/BRPI0910690B8/pt active IP Right Grant
- 2009-04-01 PL PL09727328.8T patent/PL2300478T3/pl unknown
- 2009-04-01 CN CN200980112026.2A patent/CN101983199B/zh active Active
- 2009-04-01 RS RS20160317A patent/RS54724B1/en unknown
- 2009-04-01 MY MYPI2010004191A patent/MY169766A/en unknown
- 2009-04-01 AR ARP090101179 patent/AR071577A1/es active IP Right Grant
- 2009-04-01 EP EP09727328.8A patent/EP2300478B1/en active Active
- 2009-04-01 WO PCT/EP2009/053907 patent/WO2009121919A1/en active Application Filing
- 2009-04-01 US US12/935,686 patent/US8623879B2/en active Active
- 2009-04-01 CA CA2716410A patent/CA2716410C/en active Active
- 2009-04-01 JP JP2011502384A patent/JP5391264B2/ja active Active
- 2009-04-01 HU HUE09727328A patent/HUE027771T2/en unknown
- 2009-04-01 SI SI200931454A patent/SI2300478T1/sl unknown
- 2009-04-01 SG SG2013022462A patent/SG189706A1/en unknown
- 2009-04-01 KR KR1020107021949A patent/KR101623762B1/ko active IP Right Grant
- 2009-04-01 NZ NZ58824509A patent/NZ588245A/xx unknown
- 2009-04-02 TW TW98111045A patent/TWI433850B/zh active
- 2009-04-02 UY UY31748A patent/UY31748A/es active IP Right Grant
- 2009-04-02 PE PE2009000482A patent/PE20091756A1/es active IP Right Grant
-
2010
- 2010-08-19 IL IL20771010A patent/IL207710A/en active IP Right Grant
- 2010-09-27 EC ECSP10010506 patent/ECSP10010506A/es unknown
- 2010-09-30 CO CO10121065A patent/CO6321264A2/es active IP Right Grant
- 2010-10-01 MA MA33216A patent/MA32201B1/fr unknown
-
2011
- 2011-04-11 HK HK11103607.6A patent/HK1149549A1/xx unknown
-
2013
- 2013-11-12 US US14/077,534 patent/US9096603B2/en active Active
-
2016
- 2016-06-14 CY CY20161100516T patent/CY1117626T1/el unknown
- 2016-06-15 HR HRP20160683TT patent/HRP20160683T2/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR071577A1 (es) | Pirazolo-pirimidinona para el tratamiento de trastornos del sistema nervioso central | |
CL2020000367A1 (es) | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. | |
DOP2009000258A (es) | Compuestos amino-heterociclicos | |
EA201101395A1 (ru) | Производные 1-гетероциклил-1,5-дигидропиразоло[3,4d]пиримидин-4-oha и их применение в качестве модуляторов pde9a | |
PE20211795A1 (es) | Compuestos heteroaril tetraciclicos | |
MX2020013817A (es) | Compuestos de naftiridinona sustituidos utiles como activadores de celulas t. | |
AR083849A1 (es) | Antagonistas de mdm2 de espiro-oxindol | |
CO6170406A2 (es) | Derivados de 2-alquiltio-2-quinoliniloxi-acetamida como fungicidas | |
CY1117976T1 (el) | Παραγωγα πιπεριδινης | |
AR050698A1 (es) | Compuesto de benzazepina, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento y procedimiento para la preparacion de dicho compuesto | |
UY33245A (es) | Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas | |
PA8517101A1 (es) | Derivados de tropano ùtiles en terapia | |
CR20130432A (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR047531A1 (es) | Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa | |
AR053092A1 (es) | Compuestos derivados de acido fenoxiacetico y compuestos intermediarios de sintesis | |
DOP2005000064A (es) | Nuevos compuestos | |
AR048001A1 (es) | Hidroxi - 6 - fenilantridinas que contienen tio con actividad inhibitoria de pde4 y composiciones farmaceuticas que las contienen para el tratamiento de trastornos respiratorios. | |
AR046600A1 (es) | Diazaespiroalcanos y su uso como tratamiento para enfermedades mediadas por ccr8 | |
UY32391A (es) | Compuestos amino-heterocíclicos | |
AR084553A1 (es) | DERIVADOS IMIDAZOLICOS HETEROCICLICOS INHIBIDORES DE b-SECRETASA, COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN Y USO DE LOS MISMOS PARA TRATAR ENFERMEDADES NEURODEGENERATIVAS, EN PARTICULAR ALZHEIMER | |
UY30411A1 (es) | Derivados sustituidos del acetato de 2,3,4,-tetrahidroimidazo-[1,5-a]-pirimidin-6-amina, composiciones farmacéuticas y aplicaciones | |
JP2019502763A5 (es) | ||
AR080228A1 (es) | Derivados de piridina triciclicos medicamentos que contienen tales compuestos su uso y proceso para su preparacion | |
MX2022007842A (es) | Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t. | |
AR066712A1 (es) | Pirazol-pirrolidinas como inhibidores de gamma secretasa, una composicion farmaceutica que las comprende y su uso en eltratamiento de enfermedades mediadas por la inhibicion de la sintesis del peptido beta-amiloide. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration |